Exosens is trading at 47.25 euros, up by 4.19% compared to Thursday's close of 45.35 euros. This rebound is part of a consolidation context after several weeks of intensity. Over the past seven days, the stock has shown a negligible variation of -0.11%, indicating a stabilization phase following previous movements. In the longer term, the outlook remains positive with a gain of 13.58% over three months and 176.50% over the past twelve months, significantly outperforming the CAC 40's annual performance. Trading volumes remain low this morning, accounting for only 0.04% of the capital, typical of a pre-holiday session. The CAC 40 is also marginally up (0%), suggesting that Exosens' advance is more of a local recovery than a broader market dynamic.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, the stock confirms its strength by remaining solidly above its 50-day moving average (45.81 euros), while it is still far from its psychological support at 41 euros. This setup illustrates the short-term bullish trend. The stochastic indicator generates a buy signal, supported by an RSI at 60, which, although indicating some buyer saturation, remains in a moderately balanced zone rather than in critical overbought. The MACD shows a neutral to slightly positive configuration with a histogram of 0.08, reflecting a still fragile momentum dynamic. The stock maintains a monthly volatility of 14.28%, relatively moderate, and has a remaining gap of 1.65 euros before its immediate resistance at 48.90 euros.
Nous sommes fiers de présenter notre performance sur les neuf premiers mois de l’année 2025, qui témoignent d'une croissance soutenue du chiffre d'affaires et de la marge brute ajustée, portée par la forte dynamique du secteur de la Défense.
Marché de la Défense très dynamique, forte demande pour la vision nocturne et les systèmes pour drones/anti-drones, croissance soutenue en Europe avec contribution des États-Unis et de l’Asie-Pacifique. Lancement commercial réussi des tubes 5G (plus de 5 000 commandes avant lancement).
Risks mentioned
Cession de l’activité Amplification par Micro-ondes entraînant une perte comptable sans impact de trésorerie en 2025
Dépendance aux budgets de Défense et aux évolutions géopolitiques
Risque d'intégration des acquisitions récentes
Incertitudes de la demande dans les Sciences de la Vie (marché américain)
Opportunities identified
Croissance adressable liée à la vision nocturne et aux applications drones/anti-drones
Commercialisation des tubes 5G avec commandes significatives (>5 000 tubes)
Expansion des capacités de production (+40% d’ici 2027) soutenant le développement commercial
Effets de croissance externe (Noxant, NVLS, Phasics) élargissant le marché adressable
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
